MedTrace Logo

Phase I Study of the Combination of Anlotinib With Pemetrexed or Docetaxel

NCT03566576 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2018-06-25

No results posted yet for this study

Summary

The purpose of this clinical study is to evaluate the tolerability and toxicity of different dose of Anlotinib puls Pemetrexed/Docetaxel in Second-line Treatment of Advanced Gene Negative Non-squamous Non-small Cell Lung Cancer , to provide a reference of dosage for Phase II clinical trials

Conditions

  • Non-squamous Non-small Cell Lung Cancer

Interventions

DRUG

Anlotinib

Anlotinib 8mg p.o. qd in first cohort (3 subjects). 10mg p.o. qd in second cohort (3 subjects). 12mg p.o. qd in third cohort (3 subjects).

DRUG

Pemetrexed

Pemetrexed 500mg/m2 as a 10-minute intravenous infusion on day 1 of a 21-day cycle.

DRUG

Docetaxel

Docetaxel 60mg/m2 as a 10-minute intravenous infusion on day 1 of a 21-day cycle.

Sponsors & Collaborators

  • Fujian Cancer Hospital

    lead OTHER_GOV

Principal Investigators

  • Lin Gen · Fujian Cancer Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-01
Primary Completion
2018-09-01
Completion
2018-10-01

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03566576 on ClinicalTrials.gov